comparemela.com
Home
Live Updates
Amgen Stock Adds Good Weight After CEOs Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate - Amgen (NASDAQ:AMGN) : comparemela.com
Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate - Amgen (NASDAQ:AMGN)
MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1.
Related Keywords
Novo Nordisk Wegovy ,
Robert Bradway ,
Jay Bradner ,
Eli Lilly Zepbound ,
Lilly Zepbound ,
Pfizer ,
Reuters ,
Amgen Inc ,
Novo Nordisk ,
Amgen ,
Drug Administration ,
Chief Scientific Officer Jay ,
Best Biotech ,
Fierce Pharma ,
Benzinga Pro ,
comparemela.com © 2020. All Rights Reserved.